Go Symbol Lookup
Loading...

Health Care

More

  • Cowen's "Elan" For Elan Tuesday, 8 Jul 2008 | 9:49 AM ET
    Elan

    At the risk of being ganged up on by the "Elanians" who will take umbrage with the fact that the biopharma team at Cowen and Company is not initiating coverage of the Irish drugmaker with a "screaming buy," I am blogging about the analysts' 50-page call on the stock today.

  • Win With Genentech Against the Bears Monday, 7 Jul 2008 | 11:18 PM ET

    Cramer continued with his "Cramerican Marine Field Guide to Recessions" reflecting on the 1990 Playbook (the last time we had a financial meltdown) where healthcare stocks, especially biotech were the winners then, and in Cramer's view are likely to do it again.

  • Focus on the Buying Habits of the Big Money Players Monday, 7 Jul 2008 | 9:16 PM ET

    On tonight's show we came back to one of my favorite themes, that the idea of "the market" is at best unhelpful.  You have to focus on what the big players in the market are buying and selling, and they almost always go by sector.  That's why Jim so often uses the Wall Street as fashion show metaphor.

  • How to Play the Recession Game Monday, 7 Jul 2008 | 7:25 PM ET

    Cramer tells what works in the Wall Street fashion show, what gets the big money guys to turn their heads and say, “ah, I want to own that right now,” or "I want to dump that right now", for the exact  situation we’re facing.

  • UBS And Its Guarded Outlook For Merck's Gardasil Monday, 7 Jul 2008 | 11:14 AM ET

    Shares of Merck, which have lost more than a third of their value so far this year, are under continued pressure this morning. They were at 60 bucks in early January. Today they're trading around $37. Big pharma analyst Rupesh Patel at UBS is downgrading the Dow component from Buy to Neutral because he thinks it's gonna be "range-bound near-term"...

  • Readers Get Short With Me--Over Amgen Thursday, 3 Jul 2008 | 11:08 AM ET

    Ahead of the long holiday weekend I thought this would be as good a time as any to once again go through the "Pharma's Market" mailbag. A couple of blog readers complained about my "short" story about Amgen.

  • German Stocks for a Falling Market Thursday, 3 Jul 2008 | 5:58 AM ET

    As economies around the world struggle, it's best to stay in defensive areas like health care, according to Markus Ratz, fund manager at Lupus Alpha.

  • Baby-Talking Medicare Wednesday, 2 Jul 2008 | 7:02 PM ET

    Benefits for elderly health-care providers might trickle down a lot further than you think.

  • Stop Trading!: Big Money Makes Its Move Wednesday, 2 Jul 2008 | 3:39 PM ET

    Winning sectors like coal have taken a hit. Who's on top now?

  • Biopharma Analyst Musical Chairs Wednesday, 2 Jul 2008 | 11:16 AM ET

    In the world of nearly 400 publicly-traded biotechs, analyst coverage is especially important. Many of the firms are micro caps and when an analyst initiates coverage it can help put a baby biotech on investor and reporter radar screens.

  • More Mad Politics Tuesday, 1 Jul 2008 | 6:43 PM ET

    Wall Street overlooks Washington all the time. And that's your opportunity.

  • Waking Up to Sleep Apnea Tuesday, 1 Jul 2008 | 6:28 PM ET

    Well, figuring out how to profit off it, anyway. Here’s Cramer’s pick.

  • Prescription for Profits Tuesday, 1 Jul 2008 | 6:28 PM ET

    Allscripts could see tremendous growth when a new Medicare bill is passed.

  • Abbott, Boston Scientific Stents & Stuff Tuesday, 1 Jul 2008 | 10:33 AM ET
    Heart Stent

    So, I can now safely say, with complete confidence, that Food and Drug Administration approval of the new Abbott drug-coated stent will not happen in the second quarter. Recently, at least a couple of analysts have been telling clients a decision was getting pushed out until the third quarter and one suggested that Xience won't be launched until Q4.

  • Making Money Off Medicare Monday, 30 Jun 2008 | 6:05 PM ET

    Fresenius might cash in once the new bill passes.

  • Medicare Matters Monday, 30 Jun 2008 | 6:00 PM ET

    Some lucky companies will split up $454 billion this year. But who?

  • A "Short" Story On Amgen Monday, 30 Jun 2008 | 9:04 AM ET
    AMGEN

    When combing through Barron's over the weekend I always make it a point to check out the "Short Interest" tables when they appear. I'm curious, in particular, about the ups and downs in Dendreon. Right now it's 39th on Barron's list of the Top-40 largest short positions.

  • Merck Muscles In On Migraines Friday, 27 Jun 2008 | 4:29 PM ET

    On another ugly day for the stock markets, beaten down shares of Dow component Merck rallied. The stock started picking up steam after the news broke late this morning that its late-stage experimental migraine headache drug essentially works just as well as an existing drug, but with fewer side effects.

  • Fourth of July fireworks

    FBR's Christopher Warren is out with a research note to clients this morning saying that Boston Scientific is doing deals. He writes that BSX is "reportedly bundling $1,100 (that's right, $1,100) Taxus stents with defibrillators and ultrasound devices."

  • sCredit Suisse building sign

    Credit Suisse is out today with a "fat" report on obesity. Nearly 200 pages. But besides its size, the research also stands out as one of the most unique pieces of Wall Street analysis I've ever seen.